| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5059 | tcmdc-125802 | Antimalarial; Novel inhibitor of HepG2 |
|
| DCC5060 | Tcmdc-135051 Tfa Salt | Novel Inhibitor of the malaria parasite protein kinase CLK3, inhibiting the development of liver-stage parasites, killing asexual blood-stage parasites at the trophozoite and schizont stages of the erythrocytic cycle, blocking the development of sexual ga |
|
| DCC5061 | Tcn-237 Dihydrochloride | Highly potent NR2B-selective NMDA receptor antagonist |
|
| DCC5062 | Tc-ot-39 | Nonpeptide partial agonist of oxytocin (OT) and vasopressin V2 receptors |
|
| DCC5063 | Tc-s 7005 | Potent and selective polo-like kinase 2 (PLK2) inhibitor |
|
| DCC5064 | Tcs2312 | Novel potent and selective CHK1 kinase inhibitor |
|
| DCC5065 | Tcs2314 Featured | Novel Integrin very late antigen-4 (VLA-4; α4β1) antagonist, blocking the activation of inflammatory cells. |
|
| DCC5066 | Tcs-3035 | Novel GPR35 agonist |
|
| DCC5067 | Tcs-401 | Insulin receptor sensitizing agent; Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) |
|
| DCC5068 | Tc-t 6000 | Potent equilibrative nucleoside transporter 4 (ENT4) inhibitor |
|
| DCC5069 | T-cupm | Sorafenib analogue, retaining cytotoxicity similar to sorafenib in various human cancer cell lines and strongly inhibiting growth in the NCI-60 cell line panel |
|
| DCC5070 | Td-004 | Novel degrader of the anaplastic lymphoma kinase (ALK) fusion protein, effectively inducing ALK degradation and inhibiting the growth of ALK fusion positive cell lines, SU-DHL-1 and H3122, significantly reducing the tumor growth in H3122 xenograft model |
|
| DCC5071 | Td-106 | Novel IKZF1/3 degrader, inhibiting the proliferation of multiple myeloma cells in vitro as well as in vivo |
|
| DCC5072 | Td-1211 | Novel selective opioid receptor antagonist at all three receptor types |
|
| DCC5073 | Td-428 | Novel potent BET protein degrader, inhibiting cell proliferation due to suppressed C-MYC transcription |
|
| DCC5074 | Td-5471 Hydrochloride | Novel long-acting β 2 -adrenoceptor agonist |
|
| DCC5075 | Tdcipp | Hepatotoxicity inducer, significantly up-regulating the expression of genes involved in endoplasmic reticulum stress and Toll-like receptor (TLR) pathway |
|
| DCC5076 | Tdmq20 | Novel Specific Copper Chelator, Reducing Memory Impairments in Alzheimer's Disease Mouse Models |
|
| DCC5077 | Tdp1-in-9a | Novel potent inhibitor of tyrosyl-DNA phosphodiesterase 1 (Tdp1) |
|
| DCC5078 | Tdp222669 | Novel inhibitor of the p53-Hdm2 protein-protein interaction, dose-dependently stabilized P53 and increased P21 and MDM2 expression in JAR choriocarcinoma cells, inducing the p53 regulated gene (PIG-3) and caspase activity |
|
| DCC5079 | Tdr32570 | Novel antimalarial agent |
|
| DCC5080 | Tecovirimat Hydrate Featured | Novel inhibitor of viral p37, blocking the ability of virus particles to be released from infected cells, being used for the treatment of smallpox, monkeypox, orthopoxvirus, and orthopoxviral Disease. |
|
| DCC5081 | Tefinostat | Novel monocyte/macrophage targeted histone deacetylase inhibitor |
|
| DCC5082 | Teijin Compound 1 Hydrochloride Featured | CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC50s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC50 of 24 nM. |
|
| DCC5083 | Teixobactin | Natural antibacterial agent, being active against gram-positive bacteria. |
|
| DCC5084 | Telenzepine | Potent and selective M1 antimuscarinic |
|
| DCC5085 | Telmesteine | Mucolitic agent, inhibiting activation of nuclear factor kappa-κB (NF-κB) by blocking phosphoinositide 3-kinase/protein kinase B (PI3K/Akt)/IκB kinase (IKK) activities, showing the anti-inflammatory properties on inflammation-associated skin diseases |
|
| DCC5086 | Temoporfin | Photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck, also showing activity agaimst COVID-19 Mpro |
|
| DCC5087 | Tenidap Sodium | COX/5-LOX inhibitor and cytokine-modulating anti-inflammatory agent |
|
| DCC5088 | Tertomotide | Peptide vaccine, residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), for the treatment of solid cancers |
|
